Bank of America
NVCT icon

Bank of America’s Nuvectis Pharma NVCT Stock Holding History

Bank of America’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Buy
14,847
+1,377
+10% +$11.8K ﹤0.01% 5501
2025
Q4 		$102K Buy
13,470
+5,428
+67% +$35.4K ﹤0.01% 5617
2025
Q3 		$48.4K Sell
8,042
-523
-6% -$3.6K ﹤0.01% 6848
2025
Q2 		$64K Buy
8,565
+6,909
+417% +$62.7K ﹤0.01% 6712
2025
Q1 		$16.2K Buy
1,656
+41
+3% +$295 ﹤0.01% 7020
2024
Q4 		$8.74K Buy
1,615
+855
+113% +$5.36K ﹤0.01% 7009
2024
Q3 		$4.78K Sell
760
-4
-0.5% -$26 ﹤0.01% 7021
2024
Q2 		$4.84K Sell
764
-3,011
-80% -$20.5K ﹤0.01% 7011
2024
Q1 		$31K Sell
3,775
-3,730
-50% -$31.7K ﹤0.01% 6651
2023
Q4 		$62.6K Buy
7,505
+1,367
+22% +$12.2K ﹤0.01% 6542
2023
Q3 		$79.1K Buy
6,138
+4,782
+353% +$69.3K ﹤0.01% 6346
2023
Q2 		$21.7K Buy
1,356
+1,192
+727% +$19K ﹤0.01% 6690
2023
Q1 		$2.15K Buy
164
+152
+1,267% +$1.54K ﹤0.01% 7209
2022
Q4 		$90 Buy
+12
New +$86 ﹤0.01% 7688

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of America's NVCT Position: Q1 2026 in Review

Bank of America increased its Nuvectis Pharma (NVCT) stake by 10% in Q1 2026, buying an estimated $11.8K and bringing the position to 14,847 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #5501.

Bank of America first reported a position in NVCT in Q4 2022 and has held it in 14 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Bank of America held 14,847 shares of Nuvectis Pharma worth $115K as of Q1 2026.
  • Bank of America bought 1,377 Nuvectis Pharma shares in Q1 2026, an estimated $11.8K.
  • Nuvectis Pharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5501 holding.
  • Bank of America first reported a position in Nuvectis Pharma in Q4 2022 and has held it in 14 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.